NF-kB

From Wikipedia, the free encyclopedia

NF-κB (nuclear factor-kappa B) is a protein complex which is a transcription factor. NF-κB is found in all cell types and is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Consistent with this role, incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory^[1].

Contents 1 Discovery 2 Characterization 3 Activation of NF-κB 4 Inhibitors of NF-κB 5 NF-κB's Role in Cancer and Other Diseases 6 References 7 External links

[edit] Discovery

NF-κB was first discovered in the lab of Nobel Prize laureate David Baltimore via its interaction with an 11-base pair sequence in the immunoglobulin light-chain enhancer in B cells ^[2].

[edit] Characterization

NF-κB family members share structural homology with the retroviral oncoprotein v-Rel, resulting in their classification as NF-κB/Rel proteins^[3].

There are five proteins in the mammalian NF-κB family:

• NF-κB1 (also called p50) - NFKB1
• NF-κB2 (also called p52) - NFKB2
• RelA (also named p65) - RELA
• RelB - RELB
• c-Rel REL

In addition, there are NF-κB proteins in lower organisms, such as the fruit fly Drosophila, sea urchins, and sea anemones.

While all the proteins of the NF-κB family share a Rel homology domain in their N-terminal halves, a subfamily including RelA, RelB and c-Rel also have a transactivation domain in their C-termini. In contrast, the NF-κB1 and NF-κB2 proteins are synthesized as large precursors, p105 and p100, which undergo processing to generate the mature NF-κB subunits, p50 and p52, respectively. The processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective degradation of their C-terminal region containing ankyrin repeats. While the generation of p52 from p100 is a tightly regulated process, p50 is produced from constitutive processing of p105^[4][5]

[edit] Activation of NF-κB

Part of NF-κB's importance in regulating cellular responses is that it generally belongs in the category of "rapid-acting" primary transcription factors---i.e., transcription factors which are present in cells in an inactive state and do not require new protein synthesis to be activated (other members of this family include transcription factors such as c-Jun, STATs and nuclear hormone receptors). This allows NF-κB to act as a "first responder" to harmful cellular stimuli. Stimulation of a wide variety of cell-surface receptors leads directly to NF-κB activation and fairly rapid changes in gene expression.

Many bacterial products can activate NF-κB. The identification of Toll-like receptors (TLRs) as specific pattern recognition molecules and the finding that stimulation of TLRs leads to activation of NF-κB improved our understanding of how different pathogens activate NF-κB. For example, studies have identified TLR4 as the receptor for the LPS component of Gram-Negative bacteria. TLRs are key regulators of both innate and adaptive immune responses.

Unlike RelA, RelB, and c-Rel, the p50 and p52 NF-κB subunits do not contain trans-activation domains in their C-termini. Nevertheless, these two NF-κB members play critical roles in modulating the specificity of NF-κB function. Although homodimers of p50 and p52 are generally repressors of κB transcription, both p50 and p52 participate in target gene transactivation by forming heterodimers with RelA, RelB or c-Rel^[6]. Additionally, the p50 and p52 homodimers also bind to the nuclear protein Bcl-3, forming potent transcriptional activators^[7][8][9].

[edit] Inhibitors of NF-κB

In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by a family of inhibitors, called IκBs (Inhibitor of kappa B), which are proteins that contain multiple copies of a sequence called ankyrin repeats. By virtue of their ankyrin repeat domains, the IκB proteins mask the nuclear localization signals (NLS) of NF-κB proteins and keep them sequestered in an inactive state in the cytoplasm^[10]

IκBs are a family of related proteins that have an N-terminal regulatory domain, followed by six or more ankyrin repeats and a PEST domain in their C-terminus. Although the IκB family consists of IκBα, IκBβ, IκBγ, IκBε and Bcl-3, the best studied and major IκB protein is IκBα. Due to the presence of ankyrin repeats in their C-termini, p105 and p100 also function as IκB proteins. Of all the IκB members, IκBγ is unique in that it is synthesized from the nf-kb1 gene using an internal promoter, thereby resulting in a protein which is identical to the C terminal half of p105 ^[11].

Activation of the NF-κB complexes occurs primarily via activation of a kinase called the IκB kinase (IKK). When activated by signals, usually coming from the outside of the cell, the IκB kinase phosphorylates two serine residues located in an IκB regulatory domain. When phosphorylated on these serines (e.g., serines 32 and 36 in human IκBα), the IκB inhibitor molecules are modified by a process called ubiquitination which then leads them to be degraded by a cell structure called the proteasome.

With the degradation of the IκB inhibitor, the NF-κB complex is then freed to enter the nucleus where it can 'turn on' the expression of specific genes that have DNA-binding sites for NF-κB nearby. The activation of these genes by NF-κB then leads to the given physiological response, for example, an inflammatory or immune response, a cell survival response, or cellular proliferation. NF-κB turns on expression of its own repressor, IκBα. The newly-synthesized IκBα then re-inhibits NF-κB and thus forms an auto feedback loop, that results in oscillating levels of NF-κB activity.^[12] In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-κB that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-κB may, at least in part, be involved in activation of the virus from a latent, inactive state. YopJ is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of IκB. This causes this pathogen to effectively inhibit the NF-κB pathway and thus block the immune response of a human infected with Yersinia.

[edit] NF-κB's Role in Cancer and Other Diseases

NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumors have misregulated NF-κB: that is, NF-κB is constitutively active. Active NF-κB turns on the expression of genes that keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die. In tumor cells, NF-κB is active either due to mutations in genes encoding the NF-κB transcription factors themselves or in genes that control NF-κB activity (such as IkB genes); in addition, some tumor cells secrete factors that cause NF-κB to become active. Blocking NF-κB can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of anti-tumor agents. Thus, NF-κB is the subject of much active research among pharmaceutical companies as a target for anti-cancer therapy.

Because NF-κB controls many genes involved in inflammation, it is not surprising that NF-κB is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease, arthritis, sepsis, among others. Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-κB. There is a controversial US patent (US patent 6,410,516) that applies to the discovery and use of agents that can block NF-κB for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin, Ben-Neriah and others has highlighted the importance of the connection between NF-κB, inflammation and cancer and underscored the value of therapies that regulate the activity of NF-κB.

[edit] References

1. ^ Albensi BC, Mattson MP (2000). Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse. 2000 Feb;35(2):151-9 PMID 10611641
2. ^ Sen R, Baltimore D (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986 Aug 29;46(5):705-16. PMID 3091258
3. ^ Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006 Oct 30;25(51):6680-4. PMID 17072321
4. ^ Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63. PMID 10837071
5. ^ Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 2001 Aug 24;293(5534):1495-9. PMID 11520989
6. ^ Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002 Oct;2(10):725-34. PMID 12360211
7. ^ Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. (1993) The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993 Jul;7(7B):1354-63. PMID 8330739
8. ^ Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U (1992) The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. PMID 1406939
9. ^ Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (1993) The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 1993 Mar 12;72(5):729-39 PMID 8453667
10. ^ Jacobs MD, Harrison SC (1998) Structure of an IkappaBalpha/NF-kappaB complex. Cell. 1998 Dec 11;95(6):729-31. PMID 9865693
11. ^ Inoue J, Kerr LD, Kakizuka A, Verma IM (1992) I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell. 1992 Mar 20;68(6):1109-20. PMID 1339305
12. ^ Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR (2004) Oscillations in NF-kappaB signaling control the dynamics of gene expression Science. 2004 Oct 22;306(5696):704-8. PMID 15499023

[edit] External links

• http://www.nf-kb.org
• NF-kB
• NF-kappa B
• MeSH NF-kappa+B